Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche’s MabThera approved for two vasculitis indications in UK

Roche’s MabThera approved for two vasculitis indications in UK

19th August 2013

Roche has announced that its drug MabThera has become the first therapy approved in the UK for the treatment of two potentially fatal forms of vasculitis.

The treatment has been ratified for use against the life-threatening autoimmune diseases granulomatosis with polyangiitis and microscopic polyangiitis, both of which can cause inflammation and damage of small blood vessels and frequently affect multiple organs.

MabThera has been shown to offer similar efficacy to the chemotherapy agent cyclophosphamide in treating these conditions and even provides greater efficacy among a subset of patients with relapsing disease.

Dr David Jayne, consultant in nephrology and vasculitis at Addenbrookes Hospital, said the approval "not only means that more patients will have an additional treatment option, but will also have a chance of achieving remission or getting patients back into remission when their disease has relapsed".

This comes after Roche announced earlier this month that its new advanced basal cell carcinoma drug Erivedge has also been approved in the UK.ADNFCR-8000103-ID-801626498-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.